Cardiff Oncology, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CRDF research report →
Companywww.cardiffoncology.com
Cardiff Oncology, Inc. , a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.
- CEO
- Mani Mohindru
- IPO
- 2004
- Employees
- 32
- HQ
- San Diego, CA, US
Price Chart
Valuation
- Market Cap
- $125.80M
- P/E
- -2.81
- P/S
- 259.92
- P/B
- 3.62
- EV/EBITDA
- -2.57
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -2292.56%
- Op Margin
- -9799.17%
- Net Margin
- -9249.59%
- ROE
- -95.51%
- ROIC
- -134.15%
Growth & Income
- Revenue
- $593.00K · -13.18%
- Net Income
- $-45,851,000 · -0.92%
- EPS
- $-0.69 · 27.37%
- Op Income
- $-48,960,000
- FCF YoY
- -0.51%
Performance & Tape
- 52W High
- $4.56
- 52W Low
- $1.48
- 50D MA
- $1.70
- 200D MA
- $2.10
- Beta
- 1.36
- Avg Volume
- 761.17K
Get TickerSpark's AI analysis on CRDF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 27, 26 | Aggarwal Ajay | other | 400,000 |
| Apr 27, 26 | Aggarwal Ajay | other | 0 |
| Apr 6, 26 | Muntner Joshua B | other | 0 |
| Apr 14, 26 | Smeal Tod | other | 300,000 |
| Apr 6, 26 | Muntner Joshua B | other | 486,650 |
| Mar 31, 26 | Mohindru Mani | other | 600,000 |
| Feb 13, 26 | Lindsay Brigitte Ute | other | 200,000 |
| Feb 17, 26 | Mohindru Mani | other | 200,000 |
| Jan 27, 26 | Lindsay Brigitte Ute | other | 0 |
| Jan 27, 26 | Lindsay Brigitte Ute | other | 166,320 |
Our CRDF Coverage
We haven't published any research on CRDF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CRDF Report →